---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-018694"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:55:55.462064+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# KALA BIO Q3 2023 net loss $8.7M; CHASE Phase 2b enrollment ongoing, topline data 2H 2024

## Summary
- Net loss $8.7M ($3.41 per share) vs net income $29.1M in Q3 2022 due to prior year gain on sale of commercial business.
- Cash and equivalents $56.1M at Sep 30, 2023; together with CIRM award funds expected to fuel operations into Q2 2025.
- CHASE Phase 2b trial of KPI-012 for PCED actively enrolling; topline safety and efficacy data targeted for 2H 2024.
- R&D expenses $5.6M (up $0.2M YoY); SG&A expenses $5.0M (down $4.5M YoY) after sale of commercial portfolio.
- No product revenues in Q3 2023; preclinical evaluation of KPI-014 for inherited retinal degenerative diseases initiated.

## SEC filing metadata
- accession: 0001558370-23-018694
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837023018694/0001558370-23-018694-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837023018694/kala-20231113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-018694
- JSON: https://secwatch.observer/filing/0001558370-23-018694.json
- Plain text: https://secwatch.observer/filing/0001558370-23-018694.txt

## Key facts
- Earnings Releases
  KALA BIO, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, KALA BIO, Inc. announced its financial results for the quarter ended September 30, 2023 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479419/000155837023018694/0001558370-23-018694-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.